Announcements Trials
Browse Landscape

Status

Approved for marketing 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1Interventional 1Expanded_access 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 21Precursor Cell Lymphoblastic Leukemia-Lymphoma 15Leukemia, Myelogenous, Chronic, BCR-ABL Positive 10Leukemia 10Myelodysplastic Syndromes 6Leukemia, Lymphocytic, Chronic, B-Cell 6Recurrence 5Lymphoma 5Hematologic Neoplasms 5Lymphoma, Non-Hodgkin 3Lymphoma, Mantle-Cell 3Immunologic Deficiency Syndromes 3Blast Crisis 3Waldenstrom Macroglobulinemia 2Precancerous Conditions 2Neoplasms 2Multiple Myeloma 2Mastocytosis, Systemic 2Leukemia, Promyelocytic, Acute 2Leukemia, Myeloid, Accelerated Phase 2Leukemia, Mast-Cell 2Immunoproliferative Disorders 2Immune System Diseases 2Hematologic Diseases 2Graft vs Host Disease 2Congenital Abnormalities 2Burkitt Lymphoma 2Bone Marrow Failure Disorders 2Thalassemia 1Syndrome 1

Interventions

pirtobrutinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Expanded_access × Syndrome × Other hematologic neoplasm × Clear all
NCT05172700 2024-12-18

Expanded Access Program for Pirtobrutinib for Participants With B-Cell Cancer

Eli Lilly and Company

Approved for marketing
LymphoidOther hematologic neoplasm

Hematologic Diseases, Waldenstrom Macroglobulinemia, Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡